CTRI/2019/07/020026已完成2 期
A Phase II Randomized, Double Blind, Placebo Controlled, Parallel Group,Multi-centre Study to Evaluate the Efficacy, Safety and Tolerability ofTRC160334 as an Add-on to Mesalamine in Subjects with Mild to Moderately Active Ulcerative Colitis - HEA
Torrent Pharmaceuticals Ltd India0 个研究点目标入组 222 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 222
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Subjects willing to give written informed consent to participate in the study.
- •2. Male and female subjects aged 18 to 60 years (both inclusive).
- •3. Subjects diagnosed with ulcerative colitis, confirmed by endoscopically and histologically not less than 6 weeks prior to baseline.
- •4. Subjects with active, mild to moderate disease as defined by Mayo score of 4-10 and sigmoidoscopy/colonoscopy score _ 1 (if colonoscopy has not been performed in past 1 year, it should be performed at the time of screening).
- •5. Subjects on stable dose of oral mesalamine at 2.4 gm/day or higher recommended
- •dose as tolerated for 2 weeks prior to screening.
- •6. Subjects able to comprehend the study questionnaire and adhere to the study restrictions and assessments schedule.
排除标准
- •1. Subjects with inflammation confined to _ 15 cm from anal margin; diagnosis of Crohn’s disease, indeterminate colitis or at immediate or significant risk of toxic megacolon, previous colonic surgery or recent colonoscopy suggestive of dysplastic changes or colorectal cancer, presence of fistulae, or stenosis of the intestine.
- •2. Subjects who have received systemic or rectal steroids within last 4 weeks or rectal 5-ASA within 2 weeks prior to screening.
- •3. Subjects who have received an immunosuppressant such as azathioprine,
- •methotrexate, 6-mercaptopurine, cyclosporine, tacrolimus or biologicals within 60 days prior to screening, or antibiotics within 2 weeks prior to screening, or those using anti-inflammatory drugs within 1 week prior to screening (with the exception of aspirin at doses up to 325 mg/day for cardio-protection, or paracetamol for mild acute pain, which are permitted throughout the study), or currently using any alternative or herbal medicines and refuses to discontinue.
- •4. Subjects with evidence of intestinal infection detected by positive stool culture for enteric pathogens, or Clostridium difficile or with ova and/or parasites (detected by microscopy).
- •5. Subjects with Hb < 8 g/dL or serum albumin levels < 2.5 gm/dL.
- •6. Subjects with liver enzymes (ALT, AST, ALP) > 3 times of upper limit of normal (ULN) or serum total bilirubin > 2 times of ULN, and considered clinically significant by Investigator.
- •7. Subjects with renal impairment (eGFR _ 60 mL/min/1.73 m2 by MDRD).
- •8. Participation in any interventional trial during last three months.
- •9. Pregnant or lactating women, or female of childbearing potential, who are neither
- •surgically sterilized nor willing to use reliable contraceptive methods (hormonal,
- •barrier methods or intrauterine device) or male subjects with partners of childbearing potential not willing to use reliable methods of contraception.
- •10. Subjects planning to undergo any elective surgical procedure during their participation in the study, which will have an impact on disease under evaluation(except minor procedures not associated with significant restriction of food and fluids).
- •11. Subject suffering from any other comorbid conditions or having clinically significant abnormal physical findings, laboratory results, ECG findings and/or any other clinical observation or history during the screening examination, which would interfere with the objectives of the study.
- •12. Seropositive for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).
- •13. Current or history of alcohol or drug abuse within 1 year prior to randomization.
- •14. In the opinion of the Investigator, subject is unable to communicate with study team or follow their instructions, or unlikely to cooperate/adhere with any study procedures, or keep appointments.
研究者
相似试验
招募中
1 期
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid ArthritisModerate to Severe Rheumatoid ArthritisMedDRA version: 20.0Level: HLTClassification code: 10039075Term: Rheumatoid arthritis and associated conditions Class: 10021428MedDRA version: 23.1Level: PTClassification code: 10039073Term: Rheumatoid arthritis Class: 100000004859CTIS2023-504564-42-00Anaptysbio Inc.420
进行中（未招募）
1 期
A Phase 2, Randomized, Double Blind, Placebo Controlled, Dose Escalation Study to Assess the Safety and Effects of Intravenous Conivaptan on the Hepatic Hemodynamic Response in Stable Euvolemic or Hypervolemic Cirrhotic PatientsEstudio fase II, randomizado, doble ciego, controlado con placebo, de escalonamiento de dosis para evaluar la seguridad y los efectos de Conivaptan intravenoso sobre la respuesta hemodinámica hepática en pacientes cirróticos euvolémicos o hipervolémicos estables.stable euvolemic or hypervolemic cirrhotic patients with serum sodium 115 – 140 mEq/LPacientes cirróticos euvolémicos o hipervolémicos estables con un valor de sodio sérico comprendido entre 115 y 140 mEq/LMedDRA version: 9.1Level: PTClassification code 10019641Term: Hepatic cirrhosisMedDRA version: 9.1Level: LLTClassification code 10021038Term: HyponatremiaEUCTR2007-001661-15-ESAstellas Pharma US, Inc20
进行中（未招募）
1 期
A Multinational Study to Evaluate the Safety and Activity of Enzalutamide in Combination With Exemestane in Women With Hormone-Positive Breast Cancer That Is Normal for HER-2MedDRA version: 14.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast CancerEUCTR2013-002717-35-ESMedivation, Inc.240
进行中（未招募）
1 期
Phase 2 Study of ALXN2050 in Adult Participants with Generalized Myasthenia GravisMedDRA version: 21.1Level: PTClassification code 10028417Term: Myasthenia gravisSystem Organ Class: 10029205 - Nervous system disordersMyasthenia GravisEUCTR2021-001229-26-ITALEXION PHARMACEUTICALS INCORPORATED70
进行中（未招募）
1 期
Phase 2 Study of ALXN2050 in Adult Participants with Generalized Myasthenia GravisMedDRA version: 21.1Level: PTClassification code 10028417Term: Myasthenia gravisSystem Organ Class: 10029205 - Nervous system disordersMyasthenia GravisEUCTR2021-001229-26-DEAlexion Pharmaceuticals70